A 2-Year Prospective Study on the Differences in Prognostic Factors for Major Adverse Cardiovascular, Cerebrovascular and Renal Events Between Patients with Mild and Severe Chronic Kidney Disease

Takuji Toyama, MD1, Shu Kasama, MD2, Makito Sato, MD, PhD3, Hirokazu Sano, MD4, Tetsuya Ueda, MD5, Toyoshi Sasaki, MD6, Takehiro Nakahara, MD, PhD7, Tetsuya Higuchi, MD, PhD8, Yoshito Tsushima, MD, PhD9 and Masahiko Kurabayashi, MD, PhD9

Received: October 25, 2020/Revised manuscript received: April 19, 2021/Accepted: April 20, 2021
© The Japanese Society of Nuclear Cardiology 2021

Abstract

Purpose/Method: No studies have reported on prognostic markers in patients with chronic kidney disease (CKD) according to the severity of the disease. Therefore, in this multicenter, prospective trial performed as part of the Gunma CKD SPECT Multicenter Study, we recruited 311 patients with CKD (eGFR < 60 min/mL/1.73 m²) including 50 patients on hemodialysis and followed them for 2 years. The study sample underwent stress ⁹⁹mTc-tetrofosmin SPECT for suspected or possible ischemic heart disease. We evaluated the summed stress score (SSS), summed rest score (SRS), summed difference score (SDS) and cardiac function with electrocardiogram-gated SPECT. Then, we compared the differences in prognostic markers for major adverse cardiac, cerebrovascular, and renal events (MACCRE) between patients with mild CKD (30 min/mL/1.73 m² ≤ eGFR < 60 min/mL/1.73 m²; n=184) and those with severe CKD (eGFR < 30 min/mL/1.73 m²; n=97).

Results: Of 281 patients available for analysis, 91 experienced MACCRE. In a multivariate Cox proportional hazards analysis of factors related to MACCRE, in patients with mild CKD the significant prognostic markers were SDS (P=0.002) and end-systolic volume (ESV, P=0.034); and in the patients with severe CKD, they were eGFR (P=0.03) and diabetes-mellitus (DM, P=0.023).

Conclusions: Our findings indicate that SSS and ESV are significant prognostic markers for MACCRE in patients with mild CKD and eGFR and DM are significant prognostic markers in patients with severe CKD.

Keywords: Cardiovascular events, Cerebrovascular and renal events, Chronic kidney disease, Hemodialysis, Ischemic heart disease, Nuclear imaging

Ann Nucl Cardiol 2021; 7 (1): 000–000

Cardiovascular events include a superimposed thrombus on top of a ruptured plaque (1, 2). The risk of such events is higher in chronic kidney disease (CKD), which increases platelet aggregation, platelet reactivity, and blood thrombogenicity (3). Therefore, researchers have recently recognized that impaired kidney function is an independent risk factor for all-cause mortality and adverse cardiovascular outcomes, including myocardial infarction, stroke, and progression of heart failure (4–8).

Myocardial perfusion single-photon emission computed

doi: 10.17996/anc.21-00135

1) Division of Cardiology, Toyama Cardiovascular Clinic, Maebashi, Japan
2) Clinical Research Center, Nara Medical University Graduate School of Medicine, Nara, Japan
3) Department of Internal Medicine, Tatebayashi Kosei Hospital, Tatebayashi, Japan
4) Department of Cardiovascular Medicine, Iseasaki Municipal Hospital, Iseasaki, Japan
5) Division of Cardiology, Fujioka General Hospital, Fujioka, Japan
6) Division of Cardiology, Takasaki General Medical Center, Takasaki, Japan
7) Department of Cardiovascular Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
8) Department of Diagnostic Radiology and Nuclear Medicine, Gunma University Graduate School of Medicine, Maebashi, Japan
tomography (SPECT) can accurately and noninvasively diagnose ischemic heart disease and other cardiac conditions (9–11). In addition, quantitative ECG-gated SPECT (QGS) with the computer program QGS is useful for measuring left ventricular dimensions and the left ventricular ejection fraction (LVEF) (12–14). Studies have evaluated the prognostic value of combined stress myocardial perfusion SPECT and QGS for predicting major cardiac events (9, 10, 15). A number of studies have also used combined imaging to assess the prognosis of patients with CKD (16–24). Based on the results of these studies, scintigraphic parameters were shown to be independent predictors of cardiac events, including cardiac death, heart failure, and acute myocardial infarction. However, little is known about the prognostic value of these imaging methods for patients in different stages of CKD, including patients with advanced renal dysfunction, such as those on hemodialysis. Accordingly, we performed a 2-year, prospective, multicenter cohort trial in CKD patients, including patients on hemodialysis, to evaluate whether stress myocardial perfusion SPECT and QGS quantification of SPECT could predict major adverse cardiovascular, cerebrovascular, and renal events (MACCRE). In the present study, we compared differences in prognostic markers for MACCRE between patients with mild and severe CKD.

Materials and methods

Patients and study protocol

This was a prospective multicenter cohort trial performed according to the Gunma CKD SPECT Study protocol. The enrollment period was from August 2010 to July 2012. Stress/rest myocardial perfusion SPECT was performed in 311 patients including 50 patients on hemodialysis within 2 months of enrollment. Imaging data, background factors, treatment before SPECT, and the results of other examinations were recorded. The study was completed in 2014, and this report provides the results from 2 years of follow-up. To access the relation between MACCRE and the severity of CKD, we divided patients into 2 groups on the basis of the estimated glomerular filtration rate (eGFR): those with mild CKD (30 min/mL/1.73 m² ≤ eGFR < 60 min/mL/1.73 m²) and those with severe CKD (eGFR < 30 min/mL/1.73 m²).

The inclusion criteria were as follows: 1) age 20 years or older; 2) patients scheduled to undergo myocardial perfusion SPECT and QGS because of suspected ischemic heart disease; 3) eGFR less than 60 min/mL/1.73 m²; and 4) at least 1 risk factor for coronary artery disease (hypertension, diabetes mellitus [DM], dyslipidemia, peripheral artery disease, smoking ≥ 10 cigarettes/d, family history of coronary artery disease, and history of ischemic stroke). The exclusion criteria were as follows: 1) age older than 80 years; 2) severe valvular heart disease; 3) hypertrophic cardiomyopathy or dilated cardiomyopathy; 4) allergy to tetrofosmin or its analogs; 5) severe arrhythmia that could interfere with QGS; 6) bronchospastic pulmonary disease or contraindications for vasodilator infusion; and 7) patients judged by the attending physician to be unsuitable for the study for any other reason.

Ethics

Approval from the review boards of all facilities involved in this study is compulsory. In accordance with the Declaration of Helsinki 2008, all patients will provide written, informed consent to participate in all study protocols before enrolment.

Myocardial perfusion SPECT and evaluation

The patients underwent stress and resting SPECT with 99mTc-tetrofosmin. Exercise or pharmacological stress tests or both were performed with either a stress-rest or a rest-stress sequence. Each participating hospital used a standard myocardial SPECT protocol. However, the number of detectors, matrix size, number of steps, and camera rotation range were not specified, and the acquisition conditions followed the protocol of each institution. Electrocardiogram-gated SPECT was performed under resting conditions in all patients and also under stress conditions in some patients. Stress (exercise or pharmacological) and rest blood pressure and heart rate were recorded. Gated SPECT findings were quantified with QGS software (Cedars Sinai Medical Center, Los Angeles, CA) at all participating institutions (12–14). The images and image processing procedures were surveyed separately.

The myocardial perfusion image of each participant was divided into 17 segments on each SPECT image, as recommended by the American Heart Association (25). Regional tracer uptake was assessed semiquantitatively by using the following 5-point scale: 0 = normal uptake; 1 = mildly reduced uptake; 2 = moderately reduced uptake; 3 = severely reduced uptake; and 4 = no uptake. The sum of the scores of the 17 segments in the stress and resting images was calculated as the summed stress score (SSS) and summed rest score (SRS), respectively. Then, the summed difference score (SDS) was calculated as the difference between the SSS and SRS. All myocardial SPECTs were assessed by the core laboratory.

The left ventricular end-diastolic volume (EDV) and end-systolic volume (ESV) and left ventricular ejection fraction (LVEF) were obtained from QGS analysis. Heart rate and blood pressure were also monitored during the stress tests.

Follow-up

Patients were followed up for 2 years after stress myocardial perfusion SPECT and QGS. The endpoint of the study was the incidence of MACCRE, which was defined as the occurrence of cardiac death, sudden death, non-fatal myocardial infarction
hospitalization for heart failure, cerebrovascular accidents, revascularization, renal events (i.e., initiation of hemodialysis or kidney transplantation), and other cardiovascular disease.

Revascularization immediately after myocardial SPECT is included as a cardiac event.

Other cardiovascular diseases indicate unstable angina pectoris, percutaneous transluminal angioplasty and aortic event. Hospitalization for heart failure was defined as that the appearance of cardiac pump failure caused the heart failure findings including dyspnea, fatigue, edema, decreased exercise tolerance and congestion on chest X-ray, then hospitalization was needed. It was the same in patients with hemodialysis.

Statistical analysis

Analyses were performed with JMP software (SAS Institute Inc., Cary, NC). Results are expressed as the mean ± SD. In all analyses, P<0.05 was considered statistically significant. Categorical data were compared between 2 groups by using Fisher’s exact test or the chi-square test, and differences between continuous variables were evaluated by using the unpaired t test. The groups of patients with mild or severe CKD were each divided into a MACCRE group and a non-MACCRE group. Univariate Cox proportional hazards models were created to identify independent predictors of MACCRE by using variables such as clinical characteristics, risk factors, laboratory data, and the stress myocardial perfusion SPECT and QGS parameters. Subsequently, multivariate Cox proportional hazards analysis was performed in the groups of patients with mild or severe CKD.

As cut-off values of various parameters for predicting MACCRE, we used SDS=4, ESV=105 mL, and eGFR=15 ml/min/1.73m².

Results

Clinical profile and adverse events

We were able to follow 281 of the 311 patients for 2 years and obtain reliable information about their outcome from the patients themselves, their families, and/or the participating hospitals (Figure 1). The group of patients with mild CKD (n=184) consisted of 144 men and 40 women with a mean age of 72 years (range, 55–82 years); and the group of patients with severe CKD (n=97) consisted of 64 men and 33 women with a mean age of 66 years (range, 49–76 years). Of the 281 patients, 91 experienced MACCRE (Table 1).

Results in the group of patients with mild CKD

Comparison of clinical characteristics and stress myocardial perfusion SPECT and QGS parameters between the MACCRE and non-MACCRE groups

The clinical characteristics and scintigraphic parameters of the patients with mild CKD in the MACCRE and non-MACCRE groups are shown in Table 2. Age, sex, height, body weight, body mass index, hemodialysis rate, history of....

Table 1

|          | eGFR≥30 min/mL/1.73 m² (n=184) | eGFR<30 min/mL/1.73 m² (n=97) | P    |
|----------|--------------------------------|--------------------------------|------|
| 1) Cardiac death: (n=13) | 6                              | 7                              | 0.145 |
| 2) Sudden death: (n=3)    | 2                              | 1                              | 1    |
| 3) Non-fatal myocardial infarction: (n=3) | 3                              | 0                              | 0.554 |
| 4) Hospitalization for heart failure: (n=11) | 2                              | 9                              | 0.002 |
| 5) Cerebrovascular accident: (n=7)    | 3                              | 4                              | 0.239 |
| 6) Need for revascularization: (n=36) | 29                             | 7                              | 0.042 |
| 7) Renal events: (n=12)    | 3                              | 9                              | 0.004 |
| 8) Other cardiovascular events: (n=6) | 4                              | 2                              | 1    |
| Total                | 52                             | 39                             |      |

CKD: chronic kidney disease

Other cardiovascular events: 3 patients with unstable angina pectoris, 2 patients with percutaneous transluminal angioplasty and 1 patient with a ruptured abdominal aortic aneurysm.
hypertension, dyslipidemia, prior MI, and laboratory parameters were similar in the 2 groups, but diabetes mellitus (DM) was significantly more common in the MACCRE group than in the non-MACCRE group.

Data from the perfusion SPECT studies showed that EDV, ESV, and SDS were significantly higher in the MACCRE group than in the non-MACCRE group, whereas LVEF was significantly lower. The groups showed no significant differences in the frequency of exercise stress or pharmacological stress.

Medications such as beta-blockers and statins were used more frequently in the MACCRE group than in the non-MACCRE group.

Univariate Cox proportional hazards models for MACCRE

The results of univariate Cox proportional hazards analysis of factors related to MACCRE in patients with mild CKD are shown in Table 3. EDV, ESV, LVEF, SDS, and treatment with beta-blockers, statins, or antidiabetic drugs were significant

| Table 2 | Clinical characteristics and scintigraphic parameters of the MACCRE and non-MACCRE groups in mild CKD patients (eGFR>=30 min/mL/1.73 m²) |
|---------|-----------------------------------------------------------------------------------------------------------------------------------|
|         | non-MACCRE group (n=132) | MACCRE group (n=52) | P Value |
| Age, years | 71 ± 6 | 72 ± 7 | 0.744 |
| Male gender, n (%) | 100 (76) | 44 (85) | 0.162 |
| Height, cm | 159 ± 17 | 161 ± 7 | 0.240 |
| Weight, kg | 61 ± 13 | 61 ± 10 | 0.974 |
| BMI, kg/m² | 24 ± 3 | 24 ± 4 | 0.410 |
| Hemodialysis | 0 (0) | 0 (0) | |
| Hypertension | 100 (76) | 37 (71) | 0.519 |
| Diabetes mellitus | 37 (29) | 23 (44) | 0.035 |
| Dyslipidemia | 71 (55) | 26 (50) | 0.215 |
| Prior MI | 18 (14) | 7 (13) | 0.975 |
| Hb, g/dl | 14.1 ± 9.3 | 13.1 ± 1.8 | 0.242 |
| HbA1c, % | 6.0 ± 1.5 | 6.1 ± 1.6 | 0.848 |
| eGFR, ml/min/1.73m² | 49 ± 8 | 48 ± 11 | 0.562 |
| TG, mg/dl | 153 ± 75 | 155 ± 101 | 0.920 |
| LDL, mg/dl | 101 ± 30 | 106 ± 33 | 0.399 |
| HDL, mg/dl | 49 ± 20 | 46 ± 10 | 0.331 |
| SPECT data | | | |
| Exercise stress | 44 (34) | 18 (35) | 0.976 |
| Pharmacological stress | 84 (66) | 33 (63) | 0.982 |
| EDV, mL | 92 ± 46 | 117 ± 75 | 0.032 |
| ESV, mL | 42 ± 35 | 67 ± 69 | 0.013 |
| LVEF, % | 60 ± 14 | 51 ± 19 | 0.007 |
| SSS | 3.3 ± 6.9 | 5.1 ± 7.4 | 0.129 |
| SRS | 2.7 ± 6.2 | 3.3 ± 6.1 | 0.588 |
| SDS | 0.54 ± 2.1 | 1.8 ± 4.1 | 0.041 |
| Medical treatment | | | |
| ACE-I and/or ARB | 31 (24) | 15 (29) | 0.851 |
| β-blocker | 10 (8) | 15 (29) | 0.001 |
| Vasodilators | 16 (13) | 10 (19) | 0.213 |
| Statin | 30 (23) | 29 (42) | <0.0001 |
| Antidiabetic drugs | 32 (25) | 22 (42) | 0.103 |

Values are mean +/- SD or number (%).
CKD: chronic kidney disease, BMI: body mass index, MI: myocardial infarction, eGFR: estimated glomerular filtration rate, TG: triglyceride, LDL: low-density lipoprotein, HDL: high-density lipoprotein, SPECT: single photon emission computed tomography, SSS: summed stress score, SRS: summed rest score, SDS: summed difference score, EDV: end-diastolic volume, SDV: end-systolic volume, LVEF: left ventricular ejection fraction, ACE-I: angiotensin-converting enzyme inhibitor, ARB: angiotensin receptor blocker.
Multivariate Cox analysis for MACCRE

Significant predictors for MACCRE in patients with mild CKD found by Cox multivariate analysis are shown in Table 4. According to multivariate analysis, the most important predictors of MACCRE were the SDS ($P=0.002$, hazard ratio [HR] = 1.163) and ESV ($P=0.034$, HR = 1.028).

**MACCRE-free survival rate**

Figure 2 and 3 show Kaplan-Meier curves for the MACCRE-free survival rate in patients with mild CKD after 2 years of follow-up. The event-free rate was 0.74 in the group with an SDS under 4 and 0.47 in the group with an SDS greater than or equal to 4 ($P=0.012$, log-rank test; Figure 2). In the group with an ESV less than 105 mL, the event-free rate was 0.98, and in the group with an ESV equal to or greater than 105 mL, it was 0.76 ($P=0.0002$, log-rank test; Figure 3).
Results in the group of patients with severe CKD

Comparison of clinical characteristics and stress myocardial perfusion SPECT and QGS parameters between the MACCRE and non-MACCRE groups

The clinical characteristics and scintigraphic parameters of the patients with severe CKD in the MACCRE and non-MACCRE groups are shown in Table 5. Both groups were similar with respect to age, sex, body mass index, hemodialysis rate, and history of hypertension, dyslipidemia, or MI. The prevalence of DM was significantly higher in the MACCRE group than in the non-MACCRE group, but hemoglobin (Hb) and eGFR were significantly lower in the MACCRE group than in the non-MACCRE group.

We found no significant differences between the 2 groups in the data from the perfusion SPECT studies and the frequency of exercise stress or pharmacological stress.

Medication such as vasodilators was used more frequently in the MACCRE group than in the non-MACCRE group.

Univariate Cox proportional hazards models for MACCRE

The results of univariate Cox proportional hazards analysis of factors related to MACCRE in patients with severe CKD are displayed in Table 6. The significant clinical factors were DM, Hb, eGFR, and low-density lipoproteins. With respect to pharmacotherapy, vasodilators were a significant factor.

Multivariate Cox analysis of MACCRE

The significant predictors of MACCRE in patients with severe CKD found by multivariate Cox analysis are listed in Table 7. According to the multivariate analysis, the most significant predictors of MACCRE in patients with severe CKD were DM ($P=0.023$, HR = 2.161) and eGFR ($P=0.03$, HR = 0.954).

### Table 5 Clinical characteristics and scintigraphic parameters of the MACCRE and non-MACCRE groups in severe CKD patients (eGFR < 30 min/mL/1.73 m²)

| Parameter                        | non-MACCRE group (n=58) | MACCRE group (n=39) | P Value |
|---------------------------------|-------------------------|---------------------|---------|
| Age, years                      | 66 ± 10                 | 66 ± 9              | 0.814   |
| Male gender                     | 38 (65)                 | 26 (67)             | 0.861   |
| BMI, kg/m²                      | 24 ± 3                  | 25 ± 4              | 0.340   |
| Hemodialysis                    | 24 (41)                 | 20 (51)             | 0.337   |
| Hypertension                    | 49 (84)                 | 33 (85)             | 0.986   |
| Diabetes mellitus               | 16 (28)                 | 19 (50)             | 0.034   |
| Dyslipidemia                    | 20 (34)                 | 17 (44)             | 0.365   |
| Prior MI                         | 5 (9)                   | 5 (13)              | 0.505   |
| Hb, g/dl                        | 11.4 ± 1.8              | 10.7 ± 1.7          | 0.044   |
| HbA1c, %                        | 5.9 ± 1.0               | 6.2 ± 0.9           | 0.144   |
| eGFR, ml/min/1.73 m²            | 14 ± 9                  | 9 ± 6               | 0.007   |
| TG, mg/dl                       | 132 ± 125               | 112 ± 601           | 0.293   |
| LDL, mg/dl                      | 91 ± 27                 | 80 ± 29             | 0.070   |
| HDL, mg/dl                      | 45 ± 12                 | 59 ± 44             | 0.142   |

SPECT data

| Parameter                        | non-MACCRE group (n=58) | MACCRE group (n=39) | P Value |
|---------------------------------|-------------------------|---------------------|---------|
| Exercise stress                 | 19 (33)                 | 9 (23)              | 0.976   |
| Pharmacological stress          | 39 (67)                 | 30 (77)             | 0.298   |
| EDV, mL                         | 113 ± 51                | 118 ± 534           | 0.667   |
| ESV, mL                         | 57 ± 36                 | 63 ± 40             | 0.424   |
| LVEF, %                         | 54 ± 14                 | 50 ± 13             | 0.212   |
| SSS                             | 1.8 ± 4.2               | 3.5 ± 6.4           | 0.169   |
| SRS                             | 1.2 ± 3.0               | 2.3 ± 4.4           | 0.209   |
| SDS                             | 0.6 ± 1.7               | 1.2 ± 3.2           | 0.314   |

Medical treatment

| Parameter                        | non-MACCRE group (n=58) | MACCRE group (n=39) | P Value |
|---------------------------------|-------------------------|---------------------|---------|
| ACE-I and/or ARB                | 14 (24)                 | 11 (28)             | 0.653   |
| β-blocker                       | 6 (10)                  | 5 (13)              | 0.706   |
| Vasodilators                    | 4 (7)                   | 9 (23)              | 0.022   |
| Statin                          | 7 (12)                  | 9 (15)              | 0.152   |
| Antidiabetic drugs              | 16 (28)                 | 17 (45)             | 0.103   |

All abbreviations as in Table 2.
Figure 4 and 5 shows Kaplan-Meier curves for MACCRE-free survival in patients with severe CKD after 2 years of follow-up. Figure 4 shows an event-free rate of 0.74 in the group without DM and 0.59 in the group with DM (P = 0.03, log-rank test). Figure 5 shows an event-free rate of 0.83 in the group with an eGFR equal to or greater than 15 and of 0.49 in the group with an eGFR less than 15 (P=0.005, log-rank test).

Discussion

The present study aimed to compare differences in prognostic markers for MACCRE between patients with mild and severe CKD. During the 2-year follow-up of 281 patients with CKD, including 44 patients on hemodialysis, MACCRE occurred in 52 of the patients with mild CKD and 39 patients of patients with severe CKD.

Multivariate Cox analysis showed that SDS and ESV were significantly associated with MACCRE in patients with mild CKD, and DM and eGFR were significantly associated with MACCRE in patients with severe CKD. On the basis of a large-scale prospective multicenter trial (Japanese Assessment of Cardiac Events and Survival Study, J-ACCESS), Nishimura et al. reported that stress myocardial perfusion SPECT was a significant predictor of MACCRE.

Table 6  Univariate Cox proportional hazards analysis for MACCRE in severe CKD patients (eGFR<30 min/mL/1.73 m²)

| Variate                          | Hazard ratio | 95% CI       | P Value |
|----------------------------------|--------------|--------------|---------|
| Age, years                       | 0.999        | 0.968-1.033  | 0.943   |
| Male gender                      | 1.048        | 0.549-2.105  | 0.890   |
| BMI, kg/m²                       | 1.043        | 0.952-1.135  | 0.357   |
| Hypertension                     | 1.268        | 0.674-2.392  | 0.459   |
| Diabetes mellitus                | 0.974        | 0.439-2.581  | 0.953   |
| Dyslipidemia                     | 1.990        | 1.049-3.792  | 0.036   |
| Prior MI                         | 1.680        | 0.574-3.919  | 0.313   |
| Hb, g/dl                         | 0.829        | 0.682-1.002  | 0.053   |
| HbA1c, %                         | 1.248        | 0.910-1.648  | 0.161   |
| eGFR, ml/min/1.73 m²             | 0.952        | 0.907-0.993  | 0.019   |
| TG, mg/dl                        | 0.998        | 0.992-1.001  | 0.263   |
| LDL, mg/dl                       | 0.996        | 0.973-0.999  | 0.035   |
| HDL, mg/dl                       | 1.009        | 0.998-1.016  | 0.105   |
| Exercise stress                  | 0.686        | 0.307-1.386  | 0.305   |
| Pharmacological stress           | 1.459        | 0.721-3.262  | 0.305   |
| EDV, mL                          | 1.001        | 0.995-1.008  | 0.583   |
| ESV, mL                          | 1.004        | 0.996-1.013  | 0.310   |
| LVEF, %                          | 0.985        | 0.966-1.007  | 0.180   |
| SSS                              | 1.045        | 0.986-1.098  | 0.132   |
| SRS                              | 1.050        | 0.968-1.124  | 0.221   |
| SDS                              | 1.083        | 0.954-1.184  | 0.190   |
| ACE-I and/or ARB                 | 1.044        | 0.498-0.958  | 0.904   |
| β-blocker                        | 1.310        | 0.449-3.059  | 0.586   |
| Vasodilators                     | 2.646        | 1.177-5.388  | 0.021   |
| Statin                           | 1.297        | 0.489-2.879  | 0.570   |
| Antidiabetic drugs               | 1.742        | 10.906-3.299 | 0.095   |

All abbreviations as in Table 2.

Table 7  Significant predictors for MACCRE by Cox multivariate analysis (eGFR<30 min/mL/1.73 m²)

| Variate                          | Hazard ratio | 95% CI       | P Value |
|----------------------------------|--------------|--------------|---------|
| Diabetes mellitus                | 2.161        | 1.115-4.191  | 0.023   |
| eGFR ml/min/1.73 m²              | 0.954        | 0.908-0.996  | 0.030   |
| Hb, g/dl                         | 0.831        | 0.684-1.006  | 0.058   |

All abbreviations as in Table 2.

**MACCRE-free survival rate**

Figure 4 and 5 shows Kaplan-Meier curves for MACCRE-free survival in patients with severe CKD after 2 years of follow-up. Figure 4 shows an event-free rate of 0.74 in the group without DM and 0.59 in the group with DM (P=0.03, log-rank test). Figure 5 shows an event-free rate of 0.83 in the group with an eGFR equal to or greater than 15 and of 0.49 in the group with an eGFR less than 15 (P=0.005, log-rank test).
useful prognostic tool for patients with suspected or confirmed ischemic heart disease (15). In addition, subanalysis of the J-ACCESS database revealed a relationship between major cardiac events and perfusion SPECT findings in patients with CKD (18, 19).

Although this J-ACCESS subanalysis demonstrated that SPECT had incremental value for predicting cardiac events (18,19), the study population did not include patients with end-stage renal disease requiring hemodialysis and was similar to our population of patients with mild CKD. On the other hand, several studies have reported that stress myocardial perfusion SPECT is useful for detecting ischemic heart disease and predicting cardiac events in hemodialysis patients (16, 20, 21); the population of those studies was similar to our population of patients with severe CKD.

Little is known about the prognostic value of stress myocardial perfusion SPECT for patients in all stages of CKD, including those on hemodialysis and those being conservatively managed for kidney dysfunction. Furthermore, no reports compared patients with mild and severe CKD, including patients on hemodialysis.

In the present study, SDS was a significant predictor of MACCRE in patients with mild CKD. In mild CKD patients, 56% of MACCRE was occupied by revascularization, which was connected with the myocardial ischemia. As a result, MACCRE-free survival rate was considered to be higher in an SDS under 4 than an SDS greater than or equal to 4.

In previous studies that included revascularization or unstable angina pectoris as endpoints, multivariate Cox analysis also showed that SDS was one of the significant independent variables for predicting major cardiac events in patients with CKD (16, 21, 22, 24, 25).

The main reason for performing SPECT is to evaluate myocardial ischemia, and the SDS indicates the severity of myocardial ischemia. Two studies, the COURAGE and FAME studies, reported on the importance of imaging procedures for predicting the outcome of myocardial ischemia (26, 27). In the COURAGE nuclear substudy (26), the event-free survival rate in patients with a reduction in ischemic volume of 5% or more evaluated by SPECT was significantly better than in patients with a reduction of less than 5%, even though patients with coronary artery disease (CAD) were treated by optimal therapy or percutaneous coronary intervention (PCI). The FAME study (27) evaluated myocardial ischemia by fractional flow reserve (FFR) during coronary angiography in patients with multivessel CAD and found that the event-free survival rate in patients who underwent FFR-guided PCI (ie, MI-guided PCI) was significantly better than in patients who underwent angiography-guided PCI. However, FFR is not easier to perform than SPECT. In our study, myocardial ischemia was also an important predictor of MACCRE in patients with mild CKD with suspected ischemic heart disease, indicating that SPECT can provide useful prognostic information in these patients.

ESV was another significant predictor of MACCRE in patients with mild CKD. The importance of ESV was reported in some studies (15, 28, 29). In a study in 4,031 patients with suspected or confirmed ischemic heart disease, Nishimura et al. reported that multivariate Cox analysis identified ESV as one of the most important predictors of cardiac events (including cardiac death, nonfatal MI, and severe heart failure) (15). Subanalysis of this study showed that according to multivariate Cox analysis ESV was also one of the significant predictors in patients with CKD (18).

In our study, DM was one of the main factors that influenced the incidence of cardiovascular, cerebrovascular,
and renal events in patients with severe CKD. This finding is in line with previous studies that also found that DM was one of the important predictors of major cardiac events (15, 18, 22, 30). The same is true for eGFR, which in our study was a significant predictive factor of MACCRE in patients with severe CKD and in previous studies was a significant independent predictor of major cardiac events (18, 22, 23).

Revascularization is an event that is related to myocardial ischemia. In our study, revascularization was significantly lower in patients with severe CKD than in patients with mild CKD. On the other hand, hospitalization for heart failure and renal events were significantly higher in patients with severe CKD than in patients with mild CKD. Those factors affected our results that eGFR and DM were significant predictors in patients with severe CKD. However, there were some previous studies that the parameters for myocardial SPECT were useful in patients with end-stage CKD. Momose et al. reported that SDS is a strong predictor for asymptomatic diabetic CKD patients who initiated hemodialysis (16). Hase et al. reported that myocardial perfusion defect was independent predictor in patients with end-stage renal disease (21).

In general, the initiation of hemodialysis decreases quality of life and increases the physical and mental burden on patients, and patients on maintenance hemodialysis have a high mortality rate (16, 21). Therefore, we devised MACCRE as an original endpoint for this study.

Several limitations of this study need to be considered. First, an inclusion criterion was an eGFR below 60 mL/min/1.73 m² and we did not assess control data from the general population or from patients with an eGFR greater than 60 mL/min/1.73 m². Therefore, we could not compare the value of myocardial perfusion SPECT in predicting cardiac events in patients with and without CKD. Second, the number of patients included in our study was relatively small compared with previous studies (22, 30). Further prospective investigations in a larger group of patients with CKD, including patients on hemodialysis, will be necessary to better evaluate the relations of myocardial perfusion SPECT parameters to mortality and morbidity in patients with CKD, including patients on hemodialysis.

Conclusions

Multivariate Cox analysis showed that SDS and ESV were significant predictors of MACCRE in patients with mild CKD, whereas DM and eGFR as well as myocardial perfusion SPECT parameters were significant predictors of MACCRE in patients with severe CKD. Thus, predictors of MACCRE differ between patients with mild and those with severe CKD.

Acknowledgments

We appreciate the cooperation of the many physicians and technologists at all of the hospitals that participated in the Gunma CKD SPECT study. We also thank the staff of the Gunma CKD SPECT study office for performing this study.

Sources of funding

This work was not supported by any institutions.

Conflicts of interest

The authors have no conflicts of interest to declare in relation to this article.

Reprint requests and correspondence:
Takuji Toyama, MD
Toyama Cardiovascular Clinic, 2-33-9, Aramaki-machi, Maebashi Gunma, 371-0044, Japan
E-mail: t.toyama@toyama-clinic.jp

References

1. Santos-Gallego CG, Picatoste B, Badimón JJ. Pathophysiology of acute coronary syndrome. Curr Atheroscler Rep 2014; 16: 401.
2. Santos-Gallego CG, Bayón J, Badimón JJ. Thrombi of different pathologies: implications for diagnosis and treatment. Curr Treat Options Cardiovasc Med 2010; 12: 274–91.
3. Baber U, Bander J, Karajigkar R, Yadav K, Hadi A, Theodoropolous K, et al. Combined and independent impact of diabetes mellitus and chronic kidney disease on residual platelet reactivity. Thromb Haemost 2013; 110: 118–23.
4. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, et al. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000; 36: 679–84.
5. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000; 35: 681–9.
6. Best PJM, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113–9.
7. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med 2001; 134: 629–36.
8. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003; 41: 47–55.
9. Hachamovitch R, Hayes SW, Friedman JD, Cohen I, Berman DS. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003; 107: 2900–7.
10. Hachamovitch R, Rozanski A, Shaw LJ, Stone GW, Thomson LEJ, Friedman JD, et al. Impact of ischaemia and scar on the
therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011; 32: 1012–24.

11. Matsumoto N, Sato Y, Suzuki Y, Kunimasa T, Yoda S, Iida J, et al. Prognostic value of myocardial perfusion single-photon emission computed tomography for the prediction of future cardiac events in a Japanese population: a middle-term follow-up study. Circ J 2007; 71: 1580–5.

12. Germano G, Kavanagh PB, Su HT, Mazzanti M, Kiat H, Hachamovitch R, et al. Automatic reorientation of threedimensional, transaxial myocardial perfusion SPECT images. J Nucl Med 1995; 36: 1107–14.

13. Germano G, Kiat H, Kavanagh PB, Moriel M, Mazzanti M, Su HT, et al. Automatic quantification of ejection fraction from gated myocardial perfusion SPECT. J Nucl Med 1995; 36: 2318–47.

14. Germano G, Erel J, Lewin H, Kavanagh PB, Berman DS. Automatic quantitation of regional myocardial wall motion and thickening from gated technetium-99m sestamibi myocardial perfusion single-photon emission computed tomography. J Am Coll Cardiol 1997; 30: 1360–7.

15. Nishimura T, Nakajima K, Kusuoka H, Yamashina A, Nishimura S. Prognostic study of risk stratification among Japanese patients with ischemic heart disease using gated myocardial perfusion SPECT: J-ACCESS study. Eur J Nucl Med Mol Imaging 2008; 35: 319–28.

16. Momose M, Babazono T, Kondo C, Kobayashi H, Nakajima T, Kusakabe K. Prognostic significance of stress myocardial ECG-gated perfusion imaging in asymptomatic patients with diabetic chronic kidney disease on initiation of haemodialysis. Eur J Nucl Med Mol Imaging 2009; 36: 1315–21.

17. Bhatti S, Hakeem A, Dillie KS, Cook JR, Chang SM. Prevalence, prognosis, and therapeutic implications of unrecognized left ventricular systolic dysfunction in patients with anemia and chronic kidney disease. Congest Heart Fail 2010; 16: 271–7.

18. Hatta T, Nishimura S, Nishimura T. Prognostic risk stratification of myocardial ischaemia evaluated by gated myocardial perfusion SPECT in patients with chronic kidney disease. Eur J Nucl Med Mol Imaging 2009; 36: 1835–41.

19. Muramatsu T, Nishimura S, Takeishi Y, Nishimura T. Prognostic risk stratification of cardiac events evaluated by aortic calcification in elderly patients with chronic kidney disease: sub-analysis of a J-ACCESS 3 study. Ann Nucl Cardiol 2019; 5: 35–43.

20. Dahan M, Viron BM, Faraggi M, Himbert DL, Lagallicier BJ, Kolta AM, et al. Diagnostic accuracy and prognostic value of combined dipyridamole-exercise thallium imaging in hemodialysis patients. Kidney Int 1998; 54: 255–62.

21. Hase H, Joki N, Ishikawa H, Fukuda H, Imamura Y, Saijyo T, et al. Prognostic value of stress myocardial perfusion imaging using adenosine triphosphate at the beginning of haemodialysis treatment in patients with end-stage renal disease. Nephrol Dial Transplant 2004; 19: 1161–7.

22. Yoda S, Nakashiki K, Tano A, Kasamaki Y, Kunimoto S, Matsumoto N, et al. Risk stratification of cardiovascular events in patients at all stages of chronic kidney disease using myocardial perfusion SPECT. J Cardiol 2012; 60: 377–82.

23. Joki N, Hase H, Kawano Y, Nakamura S, Nakajima K, Hatta T, et al. Myocardial perfusion imaging for predicting cardiac events in Japanese patients with advanced chronic kidney disease: 1-year interim report of the J-ACCESS 3 investigation. Eur J Nucl Med Mol Imaging 2014; 41: 1701–9.

24. Kasama S, Toyama T, Sato M, Sano H, Ueda T, Sasaki T, et al. Prognostic value of myocardial perfusion single photon emission computed tomography for major adverse cardiovascular and renal events in patients with chronic kidney disease: results from first year of follow-up of the Gunma-CKD SPECT multicenter study. Eur J Nucl Med Mol Imaging 2016; 43: 302–11.

25. Toyama T, Kasama S, Sato M, Sano H, Ueda T, Sasaki T, et al. Most important prognostic values to predict major adverse cardiovascular, cerebrovascular, and renal events in patients with chronic kidney disease including hemodialysis for 2 years. Cardiology 2019; 142: 14–23.

26. Shaw LJ, Berman DS, Maron DJ, Mancini GBJ, Hayes SW, Hartigan PM, et al; COURAGE Investigators. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy. Circulation 2008; 117: 1283–91.

27. Tonino PAL, De Bruyne B, Pijls NHJ, Siebert U, Ikeno F, van’t Veer M, et al; FAME Study Investigators. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med 2009; 360: 213–24.

28. White HD, Norris RM, Brown MA, Brandt PW, Whitlock RM, Wild CJ. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation 1987; 76: 44–51.

29. Migrino RQ, Young JB, Ellis SG, et al. End-systolic volume index at 90 to 180 minutes into reperfusion therapy for acute myocardial infarction is a strong predictor of early and late mortality. The Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO-I) Angiographic Investigators. Circulation 1997; 96: 116–21.

30. Okuyama C, Nakajima K, Hatta T, Nishimura S, Kusuoka H, Yamashita A, et al. Incremental prognostic value of myocardial perfusion single photon emission computed tomography for patients with diabetes and chronic kidney disease. Nucl Med Commun 2011; 32: 913–9.